Troglitazone induces cytotoxicity in part by promoting the degradation of peroxisome proliferator-activated receptor γ co-activator-1α protein

British Journal of Pharmacology

Volumn 161, Issue 4, 2010, Pages 771-781

  Liao, Xuemei ^a   Wang, Yanfei ^a   Wong, Chi Wai ^a  

^a GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

Author keywords

liver toxicity; mitochondrial mass; PGC 1; troglitazone

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADENOVIRUS VECTOR; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; COMPLEMENTARY DNA; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PIOGLITAZONE; PROTEASOME INHIBITOR; REACTIVE OXYGEN METABOLITE; ROSIGLITAZONE; TROGLITAZONE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; LIVER CELL; LIVER CELL CARCINOMA; LIVER TOXICITY; MEMBRANE POTENTIAL; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STRUCTURE ACTIVITY RELATION; VIRUS RECOMBINANT; WESTERN BLOTTING;

ADENOSINE TRIPHOSPHATE; APOPTOSIS; CARRIER PROTEINS; CELL SURVIVAL; CHROMANS; GENE EXPRESSION REGULATION; HEAT-SHOCK PROTEINS; HEP G2 CELLS; HUMANS; HYPOGLYCEMIC AGENTS; MITOCHONDRIA, LIVER; REACTIVE OXYGEN SPECIES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS;

EID: 77957223368     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00900.x     Document Type: Article

References (34)

1. Alexander SPH, Mathie A, Peters JA (2008). Guide to Receptors and Channels (GRAC), 3rd edition. Br J Pharmacol 153 : S1 S209. (Pubitemid 351415518)
2. Bae M-A, Song BJ (2003). Critical role of c-Jun N-terminal protein kinase activation in troglitazone-induced apoptosis of human HepG2 hepatoma cells. Mol Pharmacol 63 : 401 408. (Pubitemid 36158376)
3. Chen L, Wong C (2009). Estrogen-related receptor alpha inverse agonist enhances basal glucose uptake in myotubes through reactive oxygen species. Biol Pharm Bull 32 : 1199 1203.
4. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA (1995). Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378 : 785 789. (Pubitemid 26004411)
5. Desvergne B, Wahli W (1999). Peroxisome proliferator-activated receptors: nuclear control of metabolism 10.1210/er.20.5.649. Endocr Rev 20 : 649 688. (Pubitemid 30650602)
6. Giguere V (2008). Transcriptional control of energy homeostasis by the estrogen-related receptors. Endocr Rev 29 : 677 696.
7. Handschin C (2009). The biology of PGC-1[alpha] and its therapeutic potential. Trends Pharmacol Sci 30 : 322 329.
8. Haskins J, Rowse P, Rahbari R, de la Iglesia F (2001). Thiazolidinedione toxicity to isolated hepatocytes revealed by coherent multiprobe fluorescence microscopy and correlated with multiparameter flow cytometry of peripheral leukocytes. Arch Toxicol 75 : 425 438. (Pubitemid 32905560)
9. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP et al. (2007). Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med 357 : 28 38. (Pubitemid 47026732)
10. Kamei Y, Ohizumi H, Fujitani Y, Nemoto T, Tanaka T, Takahashi N et al. (2003). PPAR coactivator 1/ERR ligand 1 is an ERR protein ligand, whose expression induces a high-energy expenditure and antagonizes obesity. Proc Natl Acad Sci U S A 100 : 12378 12383. (Pubitemid 37271568)
11. Leclercq IA, Da Silva Morais A, Schroyen B, Van Hul N, Geerts A (2007). Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. J Hepatol 47 : 142 156. (Pubitemid 46830723)
12. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA (1995). An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor (PPAR). J Biol Chem 270 : 12953 12956.
13. Lim PLK, Liu J, Go ML, Boelsterli UA (2008). The mitochondrial superoxide/thioredoxin-2/Ask1 signaling pathway is critically involved in troglitazone-induced cell injury to human hepatocytes. Toxicol Sci 101 : 341 349.
14. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE (2007). Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298 : 1180 1188. (Pubitemid 47403104)
15. Masubuchi Y (2006). Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review. Drug Metab Pharmacokinet 21 : 347 356.
16. Nadanaciva S, Dykens JA, Bernal A, Capaldi RA, Will Y (2007). Mitochondrial impairment by PPAR agonists and statins identified via immunocaptured OXPHOS complex activities and respiration. Toxicol Appl Pharmacol 223 : 277 287. (Pubitemid 47362220)
17. Nie Y, Wong C (2009). Suppressing the activity of ERRalpha in 3T3-L1 adipocytes reduces mitochondrial biogenesis but enhances glycolysis and basal glucose uptake. J Cell Mol Med 13 : 3051 3060.
18. Niemeyer NV, Janney LM (2002). Thiazolidinedione-induced edema. Pharmacotherapy 22 : 924 929.
19. Olson BL, Hock MB, Ekholm-Reed S, Wohlschlegel JA, Dev KK, Kralli A et al. (2008). SCFCdc4 acts antagonistically to the PGC-1 transcriptional coactivator by targeting it for ubiquitin-mediated proteolysis. Genes Dev 22 : 252 264.
20. Ong MMK, Latchoumycandane C, Boelsterli UA (2007). Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities. Toxicol Sci 97 : 205 213. (Pubitemid 47072169)
21. Plosker GL, Faulds D (1999). Troglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs 57 : 409 438. (Pubitemid 29137484)
22. Sano M, Tokudome S, Shimizu N, Yoshikawa N, Ogawa C, Shirakawa K et al. (2007). Intramolecular control of protein stability, subnuclear compartmentalization, and coactivator function of peroxisome proliferator-activated receptor coactivator 1. J Biol Chem 282 : 25970 25980. (Pubitemid 47372787)
23. Scheen AJ (2004). Combined thiazolidinedione-insulin therapy: should we be concerned about safety? Drug Saf 27 : 841 856. (Pubitemid 39331683)
24. Shishido S, Koga H, Harada M, Kumemura H, Hanada S, Taniguchi E et al. (2003). Hydrogen peroxide overproduction in megamitochondria of troglitazone-treated human hepatocytes. Hepatology 37 : 136 147. (Pubitemid 36042154)
25. Staels B, Fruchart J-C (2005). Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 54 : 2460 2470. (Pubitemid 41134276)
26. Tang WH, Francis GS, Hoogwerf BJ, Young JB (2003). Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. J Am Coll Cardiol 41 : 1394 1398.
27. Tanti J-F, Jager J (2009). Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation. Curr Opin Pharmacol 9 : 753 762.
28. Tirmenstein MA, Hu CX, Gales TL, Maleeff BE, Narayanan PK, Kurali E et al. (2002). Effects of troglitazone on HepG2 viability and mitochondrial function. Toxicol Sci 69 : 131 138.
29. Vara JAF, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M (2004). PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30 : 193 204.
30. Wang J, Fang F, Huang Z, Wang Y, Wong C (2009). Kaempferol is an estrogen-related receptor [alpha] and [gamma] inverse agonist. FEBS Lett 583 : 643 647.
31. Watkins PB, Whitcomb RW (1998). Hepatic dysfunction associated with troglitazone. N Engl J Med 338 : 916 917.
32. Wu Z, Puigserver P, Andersson U, Zhang C, Adelmant G, Mootha V et al. (1999). Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 98 : 115 124. (Pubitemid 29331201)
33. Wu F, Wang J, Wang Y, Kwok T-T, Kong, S-K, Wong C (2009). Estrogen-related receptor [alpha] (ERR[alpha]) inverse agonist XCT-790 induces cell death in chemotherapeutic resistant cancer cells. Chemico-Biol Interacts 181 : 236 242.
34. Zhang H, Zhang A, Kohan DE, Nelson RD, Gonzalez FJ, Yang T (2005). Collecting duct-specific deletion of peroxisome proliferator-activated receptor blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci U S A 102 : 9406 9411. (Pubitemid 40923576)